ziftomenib + daunorubicin + cytarabine + quizartinib

A combination regimen consisting of **ziftomenib**, **daunorubicin**, **cytarabine** (known as "7+3" induction therapy), and **quizartinib**, evaluated for the treatment of acute myeloid leukemia (AML) with mutations in NPM1 or rearrangements in KMT2A. - **Ziftomenib** is a potent, selective oral menin inhibitor (menin is a co-factor for lysine methyltransferase 2A, KMT2A/MLL), inhibiting menin-KMT2A protein-protein interaction, and thereby modulating gene expression critical for leukemogenesis[5][6]. - **Daunorubicin** is an anthracycline cytotoxic agent that intercalates DNA and inhibits topoisomerase II. - **Cytarabine** is a nucleoside analog that inhibits DNA synthesis. - **Quizartinib** is a selective FLT3 inhibitor blocking aberrant signaling in AML cells harboring FLT3-ITD mutations. This combination is currently in early-phase clinical study, primarily in newly diagnosed AML patients who harbor NPM1 mutations or KMT2A rearrangements, aiming to improve remission rates and clinical outcomes over standard regimens[3][5][6].